Advanced Filters
noise

spinal-cord-disorders Clinical Trials

A listing of spinal-cord-disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 583 clinical trials
Z Zhi-Ying Wu, MD&PhD

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide Dismutase Type 1 (SOD1) Gene Mutation

18 years of age All Phase 1
V Vincenzo Di Lazzaro

Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis.

The objective of the present study is to assess the efficacy of tSMS in ALS patients. This will be achieved by monitoring: levels of NF-L and other potential innovative biomarkers, clinical progression, trough ALSFRS-R. After at least three-month follow-up, participants will be recruited to undergo biemispheric tSMS for two daily …

18 years of age All Phase N/A
G Gaoting Ma

Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS

This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.

18 - 80 years of age All Phase 1/2
C Caifang Ni

TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group. Successful participants will be randomly assigned to the two groups, with an expected enrollment of 60 participants. There will be 30 participants in the experimental …

18 years of age All Phase 1/2
J Jimin Lee, PhD

Examining Interactions Between PALS and Caregivers

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and their caregivers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS when they interact with their …

18 - 90 years of age All Phase N/A
R Reham Azab

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

18 years of age All Phase 2
L Lise Laclautre

QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up

Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway and conduction can be identified …

18 years of age All Phase N/A
E Emma Hebert

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.

18 - 75 years of age All Phase 2
J Jimin Lee, PhD

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS? Participants will read words and …

18 - 90 years of age All Phase N/A
P Philippe CORCIA, Pr

Identification of Early Markers for ALS

Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious …

18 - 90 years of age All Phase N/A

Simplify language using AI